We are thrilled to share the exciting news that Ms. Jennifer Che, our President and Managing Director, has been recognized as an IAM Global Leader 2026. To qualify, individuals must first be ranked in the gold tier of the IAM Patent 1000. From that group, IAM chooses select individuals who merit special attention ”for their ability to innovate, inspire and go above and beyond to deliver value for their clients.”

IAM has published a longer Q&A article featuring Jennifer where she answers questions about her unique career path, advice to biopharma start-ups, latest “hot IP topics”, and her approach to patent portfolio strategy. Feel free to check it out!


Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

我们的过去活动

Recommended Insights

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

2023年1月4日
New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To […]
Top crossarrow-right